GnRH analog resensitizes cisplatin-resistant human ovarian cancer cells
CSTR:
Author:
Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective:To study the effect of GnRH analog triptorelin in resensitizing cisplatin-resistant human ovarian cancer cells and to discuss the related mechanism. Methods: Cisplatin-resistant human ovarian cancer cell line OVCAR-3/CDDP was established in vitro. MTT assay was used to assess the inhibitory effects of triptorelin, cisplatin alone or a combination of both on OVCAR-3/CDDP cells. Flow cytometry was employed to observe the expression changes in epidermal growth factor receptor (EGFR) in different groups. Results: The drug restant index of OVCAR-3/CDDP cells was 13.42. The resensitizing fold of cisplatin combined with triptorelin was 3.80. The expression of EGFR had the most prominent decrease in OVCAR-3/CDDP cells in the combination group. Conclusion: Triptorelin can partially resensitize cisplatin-resistant OVCAR-3/CDDP cells, which might be related to the down-regulation of EGFR.

    Reference
    Related
    Cited by
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 28,2008
  • Revised:March 28,2008
  • Adopted:April 11,2008
  • Online: April 16,2008
  • Published:
Article QR Code